BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Validus Pharmaceuticals, Inc. Announces Acquisition of Marplan(R) (isocarboxazid), a Highly Effective Therapy for Treatment-Resistant Depression


5/14/2007 10:48:32 AM

PARSIPPANY, N.J., May 14 /PRNewswire/ -- Validus Pharmaceuticals, Inc. has acquired Marplan® (isocarboxazid) from Oxford Pharmaceuticals. Marplan® is a highly effective MAOI drug for patients who suffer the enduring and debilitating symptoms of depression and have not responded to other antidepressant drugs. Marplan® works differently than commonly-known 'SSRI drugs' because it directly blocks the action of an enzyme called monoamine oxidase. Marplan®, which was first introduced by Roche Pharmaceuticals in the early 1960's, has an established history of safety and efficacy. Validus has acquired Marplan® and will keep this important antidepressant available on the market for the thousands of patients and doctors who rely on its efficacy to control difficult-to-treat depression.

Physicians have turned to Marplan® therapy when early treatments with SSRIs and other antidepressant drugs failed to control their patients' severe symptoms of depression and also as a safe and effective alternative treatment prior to electro-convulsive therapy.

"Marplan® is an antidepressant with a distinguished track-record in a very difficult-to-treat patient population," said James Hunter, Validus Pharmaceuticals' President and CEO. "Its widely recognized efficacy and safety provide the ideal platform for our entry into the psychiatric marketplace," he added. Validus plans to begin promoting Marplan® tablets with a portfolio of customer care services for consumers and health professionals at the American Psychiatric Association Meeting beginning May 19, 2007 in San Diego.

About Validus Pharmaceuticals

Validus Pharmaceuticals is a full service pharmaceutical company, based in Parsippany, NJ. Validus is a portfolio investment of Konanda Pharma Partners, a private equity firm in New York City. Validus' business plan calls for the marketing and support of Marplan® as well as the acquisition and marketing of additional new or underutilized products that have important future potential in the treatment of central nervous system diseases. Please log on to the Validus / Marplan® website http://www.marplan.com for additional information.

About Konanda Pharma Partners

Validus Pharmaceuticals, Inc. is a portfolio investment of Konanda Pharma Partners, an investment fund focused on acquiring mature branded drugs and building portfolio companies around such products. See http://www.konanda.com for additional information about the Fund's principals and investment objectives.

Please go to the Marplan website http://www.marplan.com for Full Prescribing Information, including BOXED WARNINGS regarding increased risk of suicidality in children and adolescents. MAO-inhibitors are contraindicated with certain drugs, and potential hypertensive crises may occur with tyramine containing foods. As with all antidepressants, patients should be observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of therapy.

Source: Validus Pharmaceuticals, Inc.

>>> Discuss This Story



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES